1.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

2.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

3.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

4.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

5.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

6.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

7.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

8.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

9.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

1.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

2.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

3.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

4.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

5.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

6.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

7.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

8.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

9.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

1.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

2.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

3.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

4.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

5.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

6.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

7.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

8.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

9.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

1.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

2.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

3.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

4.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

5.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

6.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

7.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

8.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

9.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

1.

Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome

2.

Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome

3.

Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome

4.

Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome

5.

Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome

1.

A mutation in the mitochondrial aspartate/glutamate carrier leads to a more oxidizing intramitochondrial environment and an inflammatory myopathy in Dutch shepherd dogs

2.

A mutation in the mitochondrial aspartate/glutamate carrier leads to a more oxidizing intramitochondrial environment and an inflammatory myopathy in Dutch shepherd dogs

3.

A mutation in the mitochondrial aspartate/glutamate carrier leads to a more oxidizing intramitochondrial environment and an inflammatory myopathy in Dutch shepherd dogs

4.

A mutation in the mitochondrial aspartate/glutamate carrier leads to a more oxidizing intramitochondrial environment and an inflammatory myopathy in Dutch shepherd dogs

5.

A mutation in the mitochondrial aspartate/glutamate carrier leads to a more oxidizing intramitochondrial environment and an inflammatory myopathy in Dutch shepherd dogs

1.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

2.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

3.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

4.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

5.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

6.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

7.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

8.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

9.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

1.

Deleterious mutations in the tpo gene associated with familial thyroid follicular cell carcinoma in dutch german longhaired pointers

2.

Deleterious mutations in the tpo gene associated with familial thyroid follicular cell carcinoma in dutch german longhaired pointers

1.

Protofibril Assemblies of the Arctic, Dutch, and Flemish Mutants of the Alzheimer's Aβ1–40 Peptide

2.

Protofibril Assemblies of the Arctic, Dutch, and Flemish Mutants of the Alzheimer's Aβ1–40 Peptide

3.

Protofibril Assemblies of the Arctic, Dutch, and Flemish Mutants of the Alzheimer's Aβ1–40 Peptide

4.

Protofibril Assemblies of the Arctic, Dutch, and Flemish Mutants of the Alzheimer's Aβ1–40 Peptide

5.

Protofibril Assemblies of the Arctic, Dutch, and Flemish Mutants of the Alzheimer's Aβ1–40 Peptide

6.

Protofibril Assemblies of the Arctic, Dutch, and Flemish Mutants of the Alzheimer's Aβ1–40 Peptide

7.

Protofibril Assemblies of the Arctic, Dutch, and Flemish Mutants of the Alzheimer's Aβ1–40 Peptide

8.

Protofibril Assemblies of the Arctic, Dutch, and Flemish Mutants of the Alzheimer's Aβ1–40 Peptide

1.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

2.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

3.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

4.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

5.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

6.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

7.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

8.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

9.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.